Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Evaluation of contrast sensitivity and quality of life after implantation of 2 multifocal intraocular lens models

Poster Details

First Author: S. Akkaya Turhan TURKEY

Co Author(s):    E. Toker                    

Abstract Details

Purpose:

To evaluate and compare contrast visual acuity with / without glare, quality of life, spectacle independence and dysphotopsia symptoms after cataract surgery with 2 different diffractive multifocal intraocular lenses (MIOLs) implantation.

Setting:

Department of Ophthalmology, Marmara University Medical School, Istanbul, Turkey

Methods:

This prospective study enrolled cataract patients having bilateral implantation of Acrysof Restor SN6AD1 apodized MIOL (n=15 patients) or Acriva Reviol MFM 611 MIOL (n=15 patients). Binocular uncorrected distance (UDVA), intermediate (UIVA) and near (UNVA) visual acuities; contrast sensitivity measurements with and without glare (CSV-1000 E), photopic and mesopic contrast sensitivity by Pelli-Robson test,) and patient satisfaction by National Eye Institute Refractive Error Quality of Life Instrument-42 (NEI-RQL-42) questionnaire were analyzed preoperatively and postoperatively at 1, 3, 6, 12 months.

Results:

There were no statistically significant postoperative differences in the visual acuity parameters (p>0.05). Contrast sensitivity measurements, spectacle independence and dysphotpsia symptoms were not significantly different between the 2 IOL groups. There were significant improvements in 12 subscales and the overall scale of NEI-RQL-42 at 12 months after surgery (p<0.0001). Neodymium: YAG laser capsulotomy was not required in any of the eyes.

Conclusions:

Both MIOLs provided excellent and clinically relevant postoperative improvements in visual outcomes, contrast sensitivity, and quality of life.

Financial Disclosure:

NONE

Back to Poster listing